Preclinical evaluation of avutometinib (VS-6766; RAF/MEK clamp) in combination with EGFR inhibition in colorectal cancer patient- derived xenograft (PDX) models harboring KRAS mutations

被引：0
|
作者：
Wang, Chongkai
Coma, Silvia
Pachter, Jonathan
Fakih, Marwan
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
530
引用
收藏
页数：2
相关论文
共 7 条
  • [1] Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer
    Rodney, Simon
    Stewart, Adam R.
    Perez, Victoria Sanchez
    Morton, Cienne
    Pickard, Lisa A.
    Shakouri, Taleen
    Prout, Toby
    Parmar, Mona
    Turner, Alison J.
    Coma, Silvia
    Pachter, Jonathan
    Finneran, Laura
    Hall, Emma
    Spicer, James
    Minchom, Anna
    Banerji, Udai
    CANCER RESEARCH, 2023, 83 (07)
  • [2] In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer
    McNamara, Blair
    Demirkiran, Cem
    Bellone, Stefania
    Mutlu, Levent
    Zipponi, Margherita
    Verzosa, Miguel S.
    Harold, Justin
    Hartwich, Tobias M.
    Altwerger, Gary
    Ratner, Elena
    Huang, Gloria
    Clark, Mitchell
    Andikyan, Vaagn
    Azodi, Masoud
    Schwartz, Peter E.
    Dottino, Peter
    Santin, Alessandro D.
    CANCER RESEARCH, 2023, 83 (07)
  • [3] The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK
    Coma, Silvia
    Musteanu, Monica
    Caffarra, Cristina
    Mira, Alessia
    Patrucco, Enrico
    Dilly, Julien
    Aguirre, Andrew J.
    Barbacid, Mariano
    Ambrogio, Chiara
    Pachter, Jonathan A.
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [4] A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non-small cell lung cancer (NSCLC).
    Camidge, D. Ross
    Reuss, Joshua E.
    Spira, Alexander I.
    Janne, Pasi A.
    Rehman, Muneeb
    Pachter, Jonathan A.
    Patrick, Gloria
    Denis, Louis J.
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Preclinical evaluation of XPO1 inhibition with topoisomerase-I (topo-I) inhibition in colorectal cancer (CRC) cell lines and patient-derived xenograft (PDX) models
    Lentz, Robert W.
    Dominguez, Adrian
    Bagby, Stacey
    Binns, Cameron
    Leal, Alexis
    Kim, Sunnie
    Davis, Sarah Lindsey
    Lieu, Christopher H.
    Messersmith, Wells A.
    Pitts, Todd M.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [6] A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
    Govindan, Ramaswamy
    Awad, Mark M.
    Gadgeel, Shirish M.
    Pachter, Jonathan A.
    Patrick, Gloria
    Denis, Louis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Inflammatory and stem-like colorectal cancer (CRC) subtypes identified in patient-derived xenograft (PDX) models show tumor growth inhibition (TGI) by the combination of trametinib (T) and neratinib (N) irrespective of KRAS mutation (MT) status
    Pal, Rekha
    Song, Nan
    Wang, Ying
    Srinivasan, Ashok
    Lucas, Peter C.
    Allegra, Carmen J.
    Davies, Angela M.
    Lalani, Alshad S.
    Jacobs, Samuel A.
    Pogue-Geile, Katherine L.
    CANCER RESEARCH, 2018, 78 (13)
1